The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature
| Autoři | |
|---|---|
| Rok publikování | 2016 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | BIOMARKERS IN MEDICINE |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | http://www.futuremedicine.com/doi/10.2217/BMM.14.105 |
| Doi | http://dx.doi.org/10.2217/BMM.14.105 |
| Obor | Neurologie, neurochirurgie, neurovědy |
| Klíčová slova | alpha-synuclein; biomarker; CSF; diagnosis; ELISA; Parkinson's disease |
| Přiložené soubory | |
| Popis | The discovery of -synuclein (-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of -syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of -syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of -syn has yielded novel insights into the variety of -syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of -syn as biomarker. We also suggest future approaches to use of CSF -syn in neurodegenerative diseases. |
| Související projekty: |